JP2017505116A5 - - Google Patents

Download PDF

Info

Publication number
JP2017505116A5
JP2017505116A5 JP2016542739A JP2016542739A JP2017505116A5 JP 2017505116 A5 JP2017505116 A5 JP 2017505116A5 JP 2016542739 A JP2016542739 A JP 2016542739A JP 2016542739 A JP2016542739 A JP 2016542739A JP 2017505116 A5 JP2017505116 A5 JP 2017505116A5
Authority
JP
Japan
Prior art keywords
modified oligonucleotide
compound
wing segment
modified
linked nucleosides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016542739A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017505116A (ja
JP6643996B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/072303 external-priority patent/WO2015100394A1/en
Publication of JP2017505116A publication Critical patent/JP2017505116A/ja
Publication of JP2017505116A5 publication Critical patent/JP2017505116A5/ja
Application granted granted Critical
Publication of JP6643996B2 publication Critical patent/JP6643996B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016542739A 2013-12-24 2014-12-24 アンジオポエチン様3発現の調節 Expired - Fee Related JP6643996B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361920652P 2013-12-24 2013-12-24
US61/920,652 2013-12-24
PCT/US2014/072303 WO2015100394A1 (en) 2013-12-24 2014-12-24 Modulation of angiopoietin-like 3 expression

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020000628A Division JP2020072713A (ja) 2013-12-24 2020-01-07 アンジオポエチン様3発現の調節

Publications (3)

Publication Number Publication Date
JP2017505116A JP2017505116A (ja) 2017-02-16
JP2017505116A5 true JP2017505116A5 (enExample) 2018-02-08
JP6643996B2 JP6643996B2 (ja) 2020-02-12

Family

ID=53479686

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016542739A Expired - Fee Related JP6643996B2 (ja) 2013-12-24 2014-12-24 アンジオポエチン様3発現の調節
JP2020000628A Pending JP2020072713A (ja) 2013-12-24 2020-01-07 アンジオポエチン様3発現の調節

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020000628A Pending JP2020072713A (ja) 2013-12-24 2020-01-07 アンジオポエチン様3発現の調節

Country Status (19)

Country Link
US (3) US20170037409A1 (enExample)
EP (2) EP3087183B1 (enExample)
JP (2) JP6643996B2 (enExample)
KR (2) KR102198082B1 (enExample)
CN (3) CN111440795A (enExample)
AU (2) AU2014369900B2 (enExample)
BR (1) BR112016013473A2 (enExample)
CA (1) CA2931510A1 (enExample)
DK (1) DK3087183T3 (enExample)
ES (1) ES2830257T3 (enExample)
HU (1) HUE052243T2 (enExample)
IL (2) IL245707B (enExample)
MX (1) MX383753B (enExample)
NZ (1) NZ720286A (enExample)
PL (1) PL3087183T3 (enExample)
PT (1) PT3087183T (enExample)
RU (1) RU2706964C2 (enExample)
SI (1) SI3087183T1 (enExample)
WO (1) WO2015100394A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR087329A1 (es) 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
CN111440795A (zh) 2013-12-24 2020-07-24 Ionis制药公司 促血管生成素样3表达的调节
JP6975641B2 (ja) 2015-04-13 2021-12-01 アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. アンギオポエチン様3(ANGPTL3)iRNA組成物およびそれらの使用方法
SMT202300219T1 (it) * 2016-02-17 2023-09-06 Regeneron Pharma Metodi per il trattamento o la prevenzione dell’aterosclerosi mediante somministrazione di un inibitore di angptl3
EA201891979A1 (ru) 2016-03-03 2019-01-31 Ридженерон Фармасьютикалз, Инк. Способы лечения пациентов с гиперлипидемией введением ингибитора pcsk9 в комбинации с ингибитором angptl3
HUE071912T2 (hu) * 2016-04-28 2025-10-28 Regeneron Pharma Eljárások örökletes hiperkoleszterinémiában szenvendõ betegek kezelésére
CA3043768A1 (en) 2016-11-29 2018-06-07 PureTech Health LLC Exosomes for delivery of therapeutic agents
US10225273B2 (en) * 2017-01-27 2019-03-05 International Business Machines Corporation Secured event monitoring leveraging blockchain
US11920148B2 (en) 2017-02-22 2024-03-05 Crispr Therapeutics Ag Compositions and methods for gene editing
PE20201287A1 (es) 2017-09-14 2020-11-24 Arrowhead Pharmaceuticals Inc Agentes de iarn y composiciones para inhibir la expresion de la angiopoyetina tipo 3 (angptl3) y metodos de uso
WO2019105437A1 (zh) 2017-12-01 2019-06-06 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
WO2019105418A1 (zh) 2017-12-01 2019-06-06 苏州瑞博生物技术有限公司 双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途
CN110944675B9 (zh) 2017-12-01 2024-08-09 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
WO2019105414A1 (zh) 2017-12-01 2019-06-06 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
WO2019105419A1 (zh) 2017-12-01 2019-06-06 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
KR102617947B1 (ko) 2017-12-29 2023-12-27 쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드 접합체와 제조 및 그 용도
US11918600B2 (en) 2018-08-21 2024-03-05 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof
WO2020063198A1 (zh) 2018-09-30 2020-04-02 苏州瑞博生物技术有限公司 一种siRNA缀合物及其制备方法和用途
WO2020099525A2 (en) * 2018-11-13 2020-05-22 Lipigon Pharmaceuticals Ab Oligonucleotides influencing the regulation of the fatty acid metabolism
WO2020099482A2 (en) * 2018-11-13 2020-05-22 Lipigon Pharmaceuticals Ab Angptl 3 oligonucleotides influencing the regulation of the fatty acid metabolism
EP3903830A4 (en) 2018-12-28 2023-04-26 Suzhou Ribo Life Science Co., Ltd. NUCLEIC ACID, COMPOSITION AND CONJUGATE WITH NUCLEIC ACID, PROCESS FOR THEIR PREPARATION AND ITS USE
AU2020280438B2 (en) 2019-05-22 2025-03-06 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
CN111973617A (zh) * 2019-05-23 2020-11-24 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
TWI870563B (zh) * 2020-03-18 2025-01-21 美商戴瑟納製藥股份有限公司 用於抑制angptl3表現之組合物及方法
BR112022020428A2 (pt) * 2020-04-09 2023-03-07 Verve Therapeutics Inc Edição base do angptl3 e métodos de uso do mesmo para tratamento de doenças
CN116887842A (zh) * 2020-10-16 2023-10-13 赛诺菲 用于抑制angptl3的新型rna组合物和方法
CN113956345B (zh) * 2021-09-10 2024-04-23 北京大学 Angpt4蛋白及其编码基因在调控心脏损伤后的修复与再生能力中的应用
CA3241896A1 (en) 2021-12-22 2023-06-29 Regeneron Pharmaceuticals, Inc. Treatment of kidney diseases with angiopoietin like 3 (angptl3) inhibitors
WO2023134705A1 (zh) * 2022-01-11 2023-07-20 上海金中锘美生物医药科技有限公司 抑制angptl3表达的rna干扰剂及其用途
AU2023227443A1 (en) 2022-03-01 2024-10-10 Crispr Therapeutics Ag Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions
JP2025527670A (ja) * 2022-08-22 2025-08-22 アローヘッド ファーマシューティカルズ インコーポレイテッド Angptl3関連疾患及び障害の治療方法
EP4615974A1 (en) 2022-11-10 2025-09-17 Regeneron Pharmaceuticals, Inc. Treatment of kidney diseases with a combination of angiopoietin like 3 (angptl3) inhibitors and solute carrier family 5 member 2 (slc5a2) inhibitors

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US337490A (en) 1886-03-09 Haebiette a
US233722A (en) 1880-10-26 One-wheel plow
US337525A (en) 1886-03-09 Agricultural implement
US337521A (en) 1886-03-09 scaeeitt
US337505A (en) 1886-03-09 Chaeles la dow
US233717A (en) 1880-10-26 Lrrhogftapher
US337477A (en) 1886-03-09 Hoeatio j
US337478A (en) 1886-03-09 Calendar
US337488A (en) 1886-03-09 Johannes evees
US337491A (en) 1886-03-09 William h
US337479A (en) 1886-03-09 Steering-propeller
US337492A (en) 1886-03-09 Hadesty
US233690A (en) 1880-10-26 Water-conductor and joint
US337474A (en) 1886-03-09 Leander l
US337520A (en) 1886-03-09 Feancis h
US233710A (en) 1880-10-26 theqdor steinway
US337516A (en) 1886-03-09 Apparatus for burning gaseous fuel
US337513A (en) 1886-03-09 Method or process of making wire cables
US337528A (en) 1886-03-09 Waterproofing cloth
US337487A (en) 1886-03-09 Cutter-head
US337481A (en) 1886-03-09 Michael clune
US337503A (en) 1886-03-09 Tablet
US337514A (en) 1886-03-09 William m
US337526A (en) 1886-03-09 serg-eant
US337508A (en) 1886-03-09 James j
US233676A (en) 1880-10-26 Combined cane-top and match-safe
US337498A (en) 1886-03-09 Alexander horne
US233721A (en) 1880-10-26 Mechanical musical instrument
US337459A (en) 1886-03-09 Apparatus for cleaning oil
US101207A (en) 1870-03-29 Improvement in screw and screw-driver
US337497A (en) 1886-03-09 Giles j
US337484A (en) 1886-03-09 Solomon paul davis
US337506A (en) 1886-03-09 lagosse
US337460A (en) 1886-03-09 Fifth-wheel
US2699808A (en) 1944-10-06 1955-01-18 Mark W Lowe Apparatus for peeling tomatoes
US2699508A (en) 1951-12-21 1955-01-11 Selectronics Inc Method of mounting and construction of mounting for low frequency piezoelectric crystals
US5118800A (en) 1983-12-20 1992-06-02 California Institute Of Technology Oligonucleotides possessing a primary amino group in the terminal nucleotide
FR2567892B1 (fr) 1984-07-19 1989-02-17 Centre Nat Rech Scient Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5591722A (en) 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
EP0497875B1 (en) 1989-10-24 2000-03-22 Isis Pharmaceuticals, Inc. 2' modified oligonucleotides
US5670633A (en) 1990-01-11 1997-09-23 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
US5646265A (en) 1990-01-11 1997-07-08 Isis Pharmceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
GB9009980D0 (en) 1990-05-03 1990-06-27 Amersham Int Plc Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides
ES2116977T3 (es) 1990-05-11 1998-08-01 Microprobe Corp Soportes solidos para ensayos de hibridacion de acidos nucleicos y metodos para inmovilizar oligonucleotidos de modo covalente.
US6582908B2 (en) 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
DE59208572D1 (de) 1991-10-17 1997-07-10 Ciba Geigy Ag Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte
US5359044A (en) 1991-12-13 1994-10-25 Isis Pharmaceuticals Cyclobutyl oligonucleotide surrogates
FR2687679B1 (fr) 1992-02-05 1994-10-28 Centre Nat Rech Scient Oligothionucleotides.
EP0577558A2 (de) 1992-07-01 1994-01-05 Ciba-Geigy Ag Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte
EP0673559A1 (en) 1992-12-14 1995-09-27 Honeywell Inc. Motor system with individually controlled redundant windings
EP0691968B1 (en) 1993-03-30 1997-07-16 Sanofi Acyclic nucleoside analogs and oligonucleotide sequences containing them
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5446137B1 (en) 1993-12-09 1998-10-06 Behringwerke Ag Oligonucleotides containing 4'-substituted nucleotides
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5627053A (en) 1994-03-29 1997-05-06 Ribozyme Pharmaceuticals, Inc. 2'deoxy-2'-alkylnucleotide containing nucleic acid
US5597909A (en) 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US5656408A (en) 1996-04-29 1997-08-12 Xerox Corporation Coated carrier particles
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
CA2303299C (en) 1997-09-12 2016-02-23 Exiqon A/S Oligonucleotide analogues
US20030228597A1 (en) 1998-04-13 2003-12-11 Cowsert Lex M. Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation
US6043352A (en) 1998-08-07 2000-03-28 Isis Pharmaceuticals, Inc. 2'-O-Dimethylaminoethyloxyethyl-modified oligonucleotides
IL145778A0 (en) 1999-04-21 2002-07-25 American Home Prod Methods and compositions for inhibiting the function of polynucleotide sequences
DE60033927T2 (de) 1999-05-04 2007-11-29 Santaris Pharma A/S L-ribo-lna analoge
US6525191B1 (en) 1999-05-11 2003-02-25 Kanda S. Ramasamy Conformationally constrained L-nucleosides
AU6605900A (en) 1999-07-16 2001-02-05 Hyseq, Inc. Novel angiopoietin materials and methods
AU768034B2 (en) 1999-12-09 2003-11-27 Sankyo Company Limited Method of testing remedy or preventive for hyperlipemia
ATE322493T1 (de) 1999-12-30 2006-04-15 Leuven K U Res & Dev Cyclohexennukleinsäuren
EP1403367A4 (en) 2001-06-08 2005-08-17 Sankyo Co A MEDICAMENT TEST METHOD FOR TREATING OR PREVENTING DISEASES SUCH AS HYPERLIPEMIA
JP2005504020A (ja) 2001-07-03 2005-02-10 アイシス・ファーマシューティカルス・インコーポレーテッド ヌクレアーゼ耐性キメラオリゴヌクレオチド
CA2464542C (en) 2001-11-16 2015-01-20 Genentech, Inc. Composition comprising and method of using angiopoietin-like protein 3 angptl3
EP1546380A4 (en) 2002-05-28 2007-02-14 Us Genomics Inc METHODS AND APPARATUSES FOR ANALYZING SIMPLE POLYMERS
WO2004011624A2 (en) 2002-07-31 2004-02-05 Nucleonics, Inc. Double stranded rna structures and constructs, and methods for generating and using the same
US20060035344A1 (en) 2002-10-18 2006-02-16 Pachuk Catherine J Double-stranded rna structures and constructs, and methods for generating and using the same
WO2004041889A2 (en) 2002-11-05 2004-05-21 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
AU2003290596B2 (en) 2002-11-05 2011-05-12 Isis Pharmaceuticals, Inc. Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
EP2314691A3 (en) 2002-11-14 2012-01-18 Dharmacon, Inc. Fuctional and hyperfunctional siRNA
US6673661B1 (en) 2002-12-20 2004-01-06 Taiwan Semiconductor Manufacturing Co., Ltd. Self-aligned method for forming dual gate thin film transistor (TFT) device
WO2004072046A2 (en) * 2003-02-12 2004-08-26 Carex S.A. Quinoline derivatives and their use for modulation of lxr activity
US7598227B2 (en) * 2003-04-16 2009-10-06 Isis Pharmaceuticals Inc. Modulation of apolipoprotein C-III expression
WO2004106356A1 (en) 2003-05-27 2004-12-09 Syddansk Universitet Functionalized nucleotide derivatives
US20110086342A1 (en) 2003-08-22 2011-04-14 Nihon University Hepatocellular Carcinoma-Associated Gene
DK1661905T3 (da) 2003-08-28 2012-07-23 Takeshi Imanishi Hidtil ukendte syntetiske nukleinsyrer af N-O-krydsbindingstype
JP5379347B2 (ja) 2003-09-18 2013-12-25 アイシス ファーマシューティカルズ, インコーポレーテッド 4’−チオヌクレオシドおよびオリゴマー化合物
CN101052717A (zh) 2004-05-11 2007-10-10 α基因株式会社 诱发rna干扰的多核苷酸以及使用该多核苷酸的基因表达抑制方法
EP1765416A4 (en) 2004-06-03 2010-03-24 Isis Pharmaceuticals Inc DOUBLE-STRONG COMPOSITIONS WITH DIFFERENTLY MODIFIED STRANDS FOR USE IN GENE MODULATION
BRPI0513477A (pt) 2004-07-20 2008-05-06 Genentech Inc composições e processos de uso de proteìna 4 semelhante a angiotensina
DK1771474T3 (da) 2004-07-20 2010-05-31 Genentech Inc Inhibitorer af angiopoitin-like 4 protein, kombinationer og anvendelser deraf
AU2005286738A1 (en) 2004-09-17 2006-03-30 Isis Pharmaceuticals, Inc. Enhanced antisense oligonucleotides
EP1812569A2 (en) 2004-11-08 2007-08-01 K.U. Leuven Research and Development Modified nucleosides for rna interference
DOP2007000015A (es) * 2006-01-20 2007-08-31 Quark Biotech Inc Usos terapéuticos de inhibidores de rtp801
PL2314594T3 (pl) 2006-01-27 2014-12-31 Isis Pharmaceuticals Inc Zmodyfikowane w pozycji 6 analogi bicykliczne kwasów nukleinowych
DK2363481T3 (en) 2006-05-05 2017-06-26 Ionis Pharmaceuticals Inc Compounds and methods for modulating gene expression
CA2651453C (en) 2006-05-11 2014-10-14 Isis Pharmaceuticals, Inc. 5'-modified bicyclic nucleic acid analogs
AU2007257692B2 (en) * 2006-06-12 2013-11-14 Aptevo Research And Development Llc Single-chain multivalent binding proteins with effector function
US8101585B2 (en) 2006-08-04 2012-01-24 Isis Pharmaceuticals, Inc. Compositions and methods for the modulation of JNK proteins
US8093222B2 (en) 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
ES2618830T3 (es) 2006-12-08 2017-06-22 Lexicon Pharmaceuticals, Inc. Anticuerpos monoclonales contra ANGPTL3
US20100190837A1 (en) 2007-02-15 2010-07-29 Isis Pharmaceuticals, Inc. 5'-Substituted-2-F' Modified Nucleosides and Oligomeric Compounds Prepared Therefrom
EP2170917B1 (en) 2007-05-30 2012-06-27 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
US8278426B2 (en) 2007-06-08 2012-10-02 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
CA2692579C (en) 2007-07-05 2016-05-03 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
WO2009067647A1 (en) 2007-11-21 2009-05-28 Isis Pharmaceuticals, Inc. Carbocyclic alpha-l-bicyclic nucleic acid analogs
AU2009220532B2 (en) 2008-03-07 2013-10-31 National University Corporation University Of Toyama Homologous recombination method, cloning method, and kit
EP2108960A1 (en) * 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
EP2356129B1 (en) 2008-09-24 2013-04-03 Isis Pharmaceuticals, Inc. Substituted alpha-l-bicyclic nucleosides
WO2010036696A1 (en) 2008-09-24 2010-04-01 Isis Pharmaceuticals, Inc. Cyclohexenyl nucleic acid analogs
US8653047B2 (en) * 2010-01-08 2014-02-18 Isis Pharmaceuticals, Inc. Modulation of angiopoietin-like 3 expression
CN103154014B (zh) 2010-04-28 2015-03-25 Isis制药公司 修饰核苷、其类似物以及由它们制备的寡聚化合物
KR102232287B1 (ko) * 2011-06-21 2021-03-29 알닐람 파마슈티칼스 인코포레이티드 안지오포이에틴-유사 3(ANGPTL3) iRNA 조성물 및 그 사용 방법
WO2013142571A2 (en) * 2012-03-20 2013-09-26 Cornell University Assays for the identification of compounds that modulate lipid homeostasis
US9984408B1 (en) 2012-05-30 2018-05-29 Amazon Technologies, Inc. Method, medium, and system for live video cooperative shopping
CN111440795A (zh) 2013-12-24 2020-07-24 Ionis制药公司 促血管生成素样3表达的调节
KR102356388B1 (ko) * 2014-05-01 2022-01-26 아이오니스 파마수티컬즈, 인코포레이티드 안지오포이에틴-유사 3 발현을 조절하기 위한 조성물 및 방법

Similar Documents

Publication Publication Date Title
JP2017505116A5 (enExample)
RU2016130110A (ru) Способы хирургической обработки путем резания и сшивания скобками
RU2016129725A (ru) Модуляция экспрессии ангиопоэтин-подобного белка 3
JP2018199700A5 (enExample)
JP2017510271A5 (enExample)
JP2014511686A5 (enExample)
JP2020503010A5 (enExample)
JP2014530004A5 (enExample)
JP2014513954A5 (enExample)
JP2018530325A5 (enExample)
JP2019088329A5 (enExample)
JP2016533717A5 (enExample)
JP2018511307A5 (enExample)
NZ616512A (en) Modulation of hepatitis b virus (hbv) expression
JP2014521310A5 (enExample)
JP2010536787A5 (enExample)
JP2012050439A5 (enExample)
JP2020022483A5 (enExample)
IL264288B (en) Methods and compositions for modulating apolipoprotein(a) expression
JP2015507625A5 (enExample)
RU2015151200A (ru) Композиции и способы модулирования экспрессии аполипопротеина (а)
JP2016116520A5 (enExample)
RU2018134379A (ru) Олигонуклеотиды для понижения экспрессии pd-l1
JP2018535967A5 (enExample)
JP2015504650A5 (enExample)